Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel in Healthy Subjects Aged 9 to 60 Years in the Philippines

Next Previous
X
Search
Trial Profile

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel in Healthy Subjects Aged 9 to 60 Years in the Philippines

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYD TDV (Primary) ; DTaP vaccine (Primary)
  • Indications Dengue; Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi Pasteur

    • Most Recent Events

    • 10 Jun 2021 Primary endpoint has been met. (Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants) , according to Results published in the Pediatric Infectious Disease Journal
    • 10 Jun 2021 Primary endpoint has been met. (Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants) , according to Results published in the Pediatric Infectious Disease Journal
    • 10 Jun 2021 Primary endpoint has been met. (Geometric Mean Concentrations of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants) , according to Results published in the Pediatric Infectious Disease Journal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top